Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Am J Hum Genet ; 104(5): 815-834, 2019 05 02.
Article in English | MEDLINE | ID: mdl-31031012

ABSTRACT

We identified individuals with variations in ACTL6B, a component of the chromatin remodeling machinery including the BAF complex. Ten individuals harbored bi-allelic mutations and presented with global developmental delay, epileptic encephalopathy, and spasticity, and ten individuals with de novo heterozygous mutations displayed intellectual disability, ambulation deficits, severe language impairment, hypotonia, Rett-like stereotypies, and minor facial dysmorphisms (wide mouth, diastema, bulbous nose). Nine of these ten unrelated individuals had the identical de novo c.1027G>A (p.Gly343Arg) mutation. Human-derived neurons were generated that recaptured ACTL6B expression patterns in development from progenitor cell to post-mitotic neuron, validating the use of this model. Engineered knock-out of ACTL6B in wild-type human neurons resulted in profound deficits in dendrite development, a result recapitulated in two individuals with different bi-allelic mutations, and reversed on clonal genetic repair or exogenous expression of ACTL6B. Whole-transcriptome analyses and whole-genomic profiling of the BAF complex in wild-type and bi-allelic mutant ACTL6B neural progenitor cells and neurons revealed increased genomic binding of the BAF complex in ACTL6B mutants, with corresponding transcriptional changes in several genes including TPPP and FSCN1, suggesting that altered regulation of some cytoskeletal genes contribute to altered dendrite development. Assessment of bi-alleic and heterozygous ACTL6B mutations on an ACTL6B knock-out human background demonstrated that bi-allelic mutations mimic engineered deletion deficits while heterozygous mutations do not, suggesting that the former are loss of function and the latter are gain of function. These results reveal a role for ACTL6B in neurodevelopment and implicate another component of chromatin remodeling machinery in brain disease.


Subject(s)
Actins/genetics , Chromosomal Proteins, Non-Histone/genetics , DNA-Binding Proteins/genetics , Dendrites/pathology , Epilepsy/etiology , Induced Pluripotent Stem Cells/pathology , Mutation , Neurodevelopmental Disorders/etiology , Neurons/pathology , Adult , Child , Child, Preschool , Chromatin/genetics , Chromatin/metabolism , Dendrites/metabolism , Epilepsy/pathology , Female , Humans , Induced Pluripotent Stem Cells/metabolism , Infant , Male , Neurodevelopmental Disorders/pathology , Neurons/metabolism , Young Adult
2.
Can J Neurol Sci ; : 1-9, 2021 Jun 21.
Article in English | MEDLINE | ID: mdl-34663489

ABSTRACT

OBJECTIVE: Ictal semiology interpretation for differentiating psychogenic nonepileptic seizures (PNESs) and epileptic seizures (ESs) is important for the institution of appropriate treatment. Our objective was to assess the ability of different health care professionals (HCPs) or students to distinguish PNES from ES based on video-recorded seizure semiology. METHODS: This study was designed following the Standards for Reporting of Diagnostic Accuracy Studies (STARD) guidelines. We showed in a random mix 36 videos of PNES or ES (18 each) and asked 558 participants to classify each seizure. The diagnostic accuracy of various groups of HCPs or students for PNES versus ES was assessed, as well as the effect of patient age and sex. Measures of diagnostic accuracy included sensitivity, specificity, and area under the curve (AUC). RESULTS: The descending order of diagnostic accuracy (AUC) was the following (p ≤ 0.001): (1) neurologists and epileptologists; (2) neurology residents; (3) other specialists and nurses with experience in epilepsy; and (4) undergraduate medical students. Although there was a strong trend toward statistical difference, with AUC 95% confidence intervals (CIs) that were not overlapping, between epileptologists (95% CI 93, 97) compared to neurologists (95% CI 88, 91), and neurologists compared to electroencephalography technicians (95% CI 82, 87), multiple pairwise comparisons with the conservative Tukey-Kramer honest significant difference test revealed no statistical difference (p = 0.25 and 0.1, respectively). Patient age and sex did not have an effect on diagnostic accuracy in neurology specialists. CONCLUSION: Visual recognition of PNES by HCPs or students varies overall proportionately with the level of expertise in the field of neurology/epilepsy.

3.
J Clin Immunol ; 40(6): 901-916, 2020 08.
Article in English | MEDLINE | ID: mdl-32638196

ABSTRACT

Isolated neuroinflammatory disease has been described in case reports of familial hemophagocytic lymphohistiocytosis (FHL), but the clinical spectrum of disease manifestations, response to therapy and prognosis remain poorly defined. We combined an international survey with a literature search to identify FHL patients with (i) initial presentation with isolated neurological symptoms; (ii) absence of cytopenia and splenomegaly at presentation; and (iii) systemic HLH features no earlier than 3 months after neurological presentation. Thirty-eight (20 unreported) patients were identified with initial diagnoses including acute demyelinating encephalopathy, leukoencephalopathy, CNS vasculitis, multiple sclerosis, and encephalitis. Median age at presentation was 6.5 years, most commonly with ataxia/gait disturbance (75%) and seizures (53%). Diffuse multifocal white matter changes (79%) and cerebellar involvement (61%) were common MRI findings. CSF cell count and protein were increased in 22/29 and 15/29 patients, respectively. Fourteen patients progressed to systemic inflammatory disease fulfilling HLH-2004 criteria at a mean of 36.9 months after initial neurological presentation. Mutations were detected in PRF1 in 23 patients (61%), RAB27A in 10 (26%), UNC13D in 3 (8%), LYST in 1 (3%), and STXBP2 in 1 (3%) with a mean interval to diagnosis of 28.3 months. Among 19 patients who underwent HSCT, 11 neurologically improved, 4 were stable, one relapsed, and 3 died. Among 14 non-transplanted patients, only 3 improved or had stable disease, one relapsed, and 10 died. Isolated CNS-HLH is a rare and often overlooked cause of inflammatory brain disease. HLH-directed therapy followed by HSCT seems to improve survival and outcome.


Subject(s)
Lymphohistiocytosis, Hemophagocytic/diagnosis , Phenotype , Adolescent , Adult , Age of Onset , Alleles , Biomarkers , Biopsy , Child , Child, Preschool , Disease Progression , Female , Genetic Predisposition to Disease , Genotype , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Humans , Infant , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphohistiocytosis, Hemophagocytic/metabolism , Magnetic Resonance Imaging , Male , Mutation , Neuroimaging , Symptom Assessment , Young Adult
4.
Am J Hum Genet ; 94(6): 891-7, 2014 Jun 05.
Article in English | MEDLINE | ID: mdl-24814191

ABSTRACT

Epileptic encephalopathies are increasingly thought to be of genetic origin, although the exact etiology remains uncertain in many cases. We describe here three girls from two nonconsanguineous families affected by a clinical entity characterized by dysmorphic features, early-onset intractable epilepsy, intellectual disability, and cortical blindness. In individuals from each family, brain imaging also showed specific changes, including an abnormally marked pontobulbar sulcus and abnormal signals (T2 hyperintensities) and atrophy in the occipital lobe. Exome sequencing performed in the first family did not reveal any gene with rare homozygous variants shared by both affected siblings. It did, however, show one gene, DOCK7, with two rare heterozygous variants (c.2510delA [p.Asp837Alafs(∗)48] and c.3709C>T [p.Arg1237(∗)]) found in both affected sisters. Exome sequencing performed in the proband of the second family also showed the presence of two rare heterozygous variants (c.983C>G [p.Ser328(∗)] and c.6232G>T [p.Glu2078(∗)]) in DOCK7. Sanger sequencing confirmed that all three individuals are compound heterozygotes for these truncating mutations in DOCK7. These mutations have not been observed in public SNP databases and are predicted to abolish domains critical for DOCK7 function. DOCK7 codes for a Rac guanine nucleotide exchange factor that has been implicated in the genesis and polarization of newborn pyramidal neurons and in the morphological differentiation of GABAergic interneurons in the developing cortex. All together, these observations suggest that loss of DOCK7 function causes a syndromic form of epileptic encephalopathy by affecting multiple neuronal processes.


Subject(s)
Blindness, Cortical/genetics , Epilepsy/genetics , GTPase-Activating Proteins/genetics , Intellectual Disability/genetics , Child , Child, Preschool , Epilepsies, Myoclonic/genetics , Exome , Female , GTPase-Activating Proteins/metabolism , Genes, Recessive , Guanine Nucleotide Exchange Factors/genetics , Heterozygote , Homozygote , Humans , Infant , Male , Mutation , Pedigree , Phenotype , Polymorphism, Single Nucleotide , Sequence Analysis, DNA , Spasms, Infantile/genetics
5.
Hum Mol Genet ; 23(18): 4846-58, 2014 Sep 15.
Article in English | MEDLINE | ID: mdl-24781210

ABSTRACT

Infantile spasms (IS) is an early-onset epileptic encephalopathy of unknown etiology in ∼40% of patients. We hypothesized that unexplained IS cases represent a large collection of rare single-gene disorders. We investigated 44 children with unexplained IS using comparative genomic hybridisation arrays (aCGH) (n = 44) followed by targeted sequencing of 35 known epilepsy genes (n = 8) or whole-exome sequencing (WES) of familial trios (n = 18) to search for rare inherited or de novo mutations. aCGH analysis revealed de novo variants in 7% of patients (n = 3/44), including a distal 16p11.2 duplication, a 15q11.1q13.1 tetrasomy and a 2q21.3-q22.2 deletion. Furthermore, it identified a pathogenic maternally inherited Xp11.2 duplication. Targeted sequencing was informative for ARX (n = 1/14) and STXBP1 (n = 1/8). In contrast, sequencing of a panel of 35 known epileptic encephalopathy genes (n = 8) did not identify further mutations. Finally, WES (n = 18) was very informative, with an excess of de novo mutations identified in genes predicted to be involved in neurodevelopmental processes and/or known to be intolerant to functional variations. Several pathogenic mutations were identified, including de novo mutations in STXBP1, CASK and ALG13, as well as recessive mutations in PNPO and ADSL, together explaining 28% of cases (5/18). In addition, WES identified 1-3 de novo variants in 64% of remaining probands, pointing to several interesting candidate genes. Our results indicate that IS are genetically heterogeneous with a major contribution of de novo mutations and that WES is significantly superior to targeted re-sequencing in identifying detrimental genetic variants involved in IS.


Subject(s)
Chromosomes, Human/genetics , Mutation , Spasms, Infantile/genetics , Child, Preschool , Chromosome Deletion , Chromosome Duplication , Comparative Genomic Hybridization , DNA Copy Number Variations , Genetic Predisposition to Disease , Genetic Variation , Humans , Infant , Infant, Newborn , Male , Oligonucleotide Array Sequence Analysis , Sequence Analysis, DNA , Spasms, Infantile/pathology , Tetrasomy
6.
Nat Genet ; 31(2): 184-9, 2002 Jun.
Article in English | MEDLINE | ID: mdl-11992121

ABSTRACT

Although many genes that predispose for epilepsy in humans have been determined, those that underlie the classical syndromes of idiopathic generalized epilepsy (IGE) have yet to be identified. We report that an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy. Compared with wildtype receptors, GABA(A) receptors that contain the mutant subunit show a lesser amplitude of GABA-activated currents in vitro, indicating that seizures may result from loss of function of this inhibitory ligand-gated channel. Our results confirm that mutation of GABRA1 predisposes towards a common idiopathic generalized epilepsy syndrome in humans.


Subject(s)
Mutation, Missense , Myoclonic Epilepsy, Juvenile/genetics , Receptors, GABA-A/genetics , Adolescent , Adult , Amino Acid Sequence , Amino Acid Substitution/genetics , Child , Child, Preschool , Epilepsy, Generalized/etiology , Epilepsy, Generalized/genetics , Genes, Dominant , Genetic Predisposition to Disease , Humans , Molecular Sequence Data , Mutation, Missense/genetics , Myoclonic Epilepsy, Juvenile/etiology , Pedigree
7.
Pediatr Neurol ; 148: 148-151, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37722300

ABSTRACT

BACKGROUND: Several specific syndromes within the RASopathies spectrum lead to an increased risk of seizures up to developing refractory epileptic encephalopathy. Management remains symptomatic. METHODS: Here we report two patients treated with trametinib, a MEK1-2 inhibitor, as a precision strategy for drug-resistant epilepsy. Patient 1 is a six-year-old girl with cardiofaciocutaneous syndrome (BRAF p.F595L, germline mutation), and Patient 2 is a 14-month-old boy with Schimmelpenning syndrome (KRAS p.G12D, postzygotic somatic mutation). Trametinib was initiated at a dosage of 0.025 mg/kg/day. RESULTS: Patient 1 had multiple seizures per day, multifocal motor to bilateral tonic-clonic. Electroencephalography (EEG) showed a dramatic reduction in EEG discharges three months after trametinib onset, while a marked clinical improvement occurred after about five months, at the same dosage, and the girl is currently seizure-free for more than six months. Patient 2 had left cerebral hemiatrophy leading to right focal motor seizures, multiple per week to multiple per day, since the age of three months. On trametinib, he experienced an early benefit, remaining seizure-free for more than three months. However, after six months we observed recurrence of seizures. After 22 months of treatment, trametinib was discontinued because of a suspected drug-induced inflammatory colitis. After discontinuation, we observed a significant clinical and EEG "rebound effect." CONCLUSIONS: We provide proof of concept that MEK inhibition is a promising approach for the treatment of patients with refractory epilepsy with selected germline and mosaic RASopathies. Future trials are encouraged to better investigate their potentials and limitations.

8.
Front Hum Neurosci ; 17: 1253529, 2023.
Article in English | MEDLINE | ID: mdl-37964801

ABSTRACT

Introduction: Pediatric frontal and temporal lobe epilepsies (FLE, TLE) have been associated with language impairments and structural and functional brain alterations. However, there is no clear consensus regarding the specific patterns of cerebral reorganization of language networks in these patients. The current study aims at characterizing the cerebral language networks in children with FLE or TLE, and the association between brain network characteristics and cognitive abilities. Methods: Twenty (20) children with FLE or TLE aged between 6 and 18 years and 29 age- and sex-matched healthy controls underwent a neuropsychological evaluation and a simultaneous functional near-infrared spectroscopy and electroencephalography (fNIRS-EEG) recording at rest and during a receptive language task. EEG was used to identify potential subclinical seizures in patients. We removed these time intervals from the fNIRS signal to investigate language brain networks and not epileptogenic networks. Functional connectivity matrices on fNIRS oxy-hemoglobin concentration changes were computed using cross-correlations between all channels. Results and discussion: Group comparisons of residual matrices (=individual task-based matrix minus individual resting-state matrix) revealed significantly reduced connectivity within the left and between hemispheres, increased connectivity within the right hemisphere and higher right hemispheric local efficiency for the epilepsy group compared to the control group. The epilepsy group had significantly lower cognitive performance in all domains compared to their healthy peers. Epilepsy patients' local network efficiency in the left hemisphere was negatively associated with the estimated IQ (p = 0.014), suggesting that brain reorganization in response to FLE and TLE does not allow for an optimal cognitive development.

9.
Dev Med Child Neurol ; 54(3): 284-6, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22188130

ABSTRACT

Hemimegalencephaly is a rare congenital brain malformation, usually associated with mental retardation, * refractory epilepsy, and progressive neurological deficits. We report the case of a 19-year-old female with de novo diagnosis of right hemimegalencephaly, normal intellectual function, and history of non-refractory epilepsy. She presented with weakness and paraesthesia of the left leg. Extensive evaluation was negative for other causes for the weakness, which was attributed to progressive neurological damage secondary to long-standing subclinical epileptic activity in the hemimegalencephalic hemisphere. This patient underwent a cerebral fluorodeoxyglucose positron emission tomography that demonstrated near-normal cortical metabolism. Formal neuropsychological evaluation revealed mild deficits in the affected hemisphere, but preserved general intellectual function. This case illustrates the wide phenotypic variations in this condition and raises questions about prenatal counselling for hemimegalencephaly.


Subject(s)
Epilepsy/etiology , Malformations of Cortical Development/complications , Brain/diagnostic imaging , Brain/pathology , Epilepsy/diagnosis , Female , Humans , Magnetic Resonance Imaging , Positron-Emission Tomography , Young Adult
10.
Am J Emerg Med ; 30(3): 456-63, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21296523

ABSTRACT

OBJECTIVE: The objective of this study is to evaluate the effectiveness of prochlorperazine and the rate of akathisia in children with severe migraine. METHODS: The study is a prospective cohort of a convenient sample of patients younger than 18 years old diagnosed with migraine and treated with intravenous prochlorperazine in adjunction with diphenhydramine in the emergency department. The evaluation of pain and akathisia was performed before the treatment and was repeated 60 minutes later and before discharge. A telephone follow-up was completed to assess relapse in pain and presence of akathisia. The effectiveness of prochlorperazine was determined using different outcomes: 50% reduction of pain, pain-free patients, treatment failure, and relapse of pain. RESULTS: Of the 79 patients included in the study for 25 months, 64 (81%) either met the International Headache Society criteria or had a diagnosis of migraine confirmed by a neurologist at follow-up. Among these patients, 47 (100%) of 47 had a 50% reduction of pain, and 24 (50%) of 48 were pain free at discharge. Only 14 (22%) of 64 patients had a treatment failure. However, 43 (68%) of 63 patients had a relapse of their headache within the first week after discharge. Overall, among the 79 patients, 4 (5%) had a definitive diagnosis of akathisia, but 27 (34%) other patients presented symptoms suggesting a possible diagnosis of akathisia. CONCLUSION: Prochlorperazine seems very effective to decrease pain on a short-term basis in children. However, more than two thirds of the patients, overall, had a relapse of their migraine at home in the first week. Despite the use of diphenhydramine, akathisia remains a concern.


Subject(s)
Akathisia, Drug-Induced/etiology , Dopamine Antagonists/therapeutic use , Migraine Disorders/drug therapy , Prochlorperazine/therapeutic use , Adolescent , Akathisia, Drug-Induced/epidemiology , Child , Diphenhydramine/therapeutic use , Dopamine Antagonists/adverse effects , Drug Therapy, Combination , Emergency Service, Hospital , Female , Follow-Up Studies , Humans , Hypnotics and Sedatives/therapeutic use , Male , Migraine Disorders/complications , Prochlorperazine/adverse effects , Prospective Studies , Recurrence , Treatment Outcome
11.
Rev Prat ; 62(10): 1401-5, 2012 Dec.
Article in French | MEDLINE | ID: mdl-23424921

ABSTRACT

Epilepsy surgery is now accepted as a well proven therapeutic strategy for resistant epileptic patients either adults or children. Even though investigations and surgical techniques are similar in both groups, epileptic surgery in paediatric patients has some particularities. Epileptic aetiologies can differ in children, the disease occurs in an immature brain, at a time of intense plasticity, especially in younger patients. When treating a paediatric epileptic patient, one must not only consider seizure control but also cognitive, social and behavioural developments. Surgery should be considered in all patients with refractory epilepsy and potential candidates to surgery should be oriented to a specialized center, where a multimodal and multidisciplinary workup is available, allowing to determine if surgery is to be considered, depending on the results.


Subject(s)
Epilepsy/surgery , Neurosurgery/methods , Pediatrics/methods , Adult , Child , Epilepsy/diagnosis , Epilepsy/epidemiology , Humans , Neuroimaging/methods , Recurrence
12.
Per Med ; 19(5): 423-434, 2022 09.
Article in English | MEDLINE | ID: mdl-35830229

ABSTRACT

Aim: To evaluate clinicians' and patients' perceptions of pharmacogenetic testing in a clinical setting. Materials & methods: This is a pragmatic mixed-method prospective observational study. Hospital pharmacists and neurologists participated in focus groups regarding pharmacogenetic testing; patients who received pharmacogenetic testing and their community pharmacists completed surveys to assess their perception of these tests. Results: Most study participants had a positive view of pharmacogenetic testing. Three major themes were identified from the focus groups: receptiveness to pharmacogenetic testing, pharmacogenetic test characteristics and integrating pharmacogenetic tests into practice. Conclusion: The views reported are encouraging for the eventual implementation of pharmacogenetics in practice. Local integration of these tests is an essential step to improve patient care through personalized medicine.


Genetic tests can help predict patients' response to medication. This study aimed to evaluate clinicians' and patients' perceptions of these genetic tests. Pediatric patients, with epilepsy, were tested and completed a survey to assess their perception of these tests. A survey was also completed by their community pharmacists, and virtual discussion groups were held with hospital pharmacists and neurologists. Most participants had a positive view of these tests, with three major themes identified from the discussion groups: receptiveness to testing, test characteristics and integration of tests into practice. The views reported are encouraging for the eventual implementation of these tests in practice, an essential step to improve patient care through personalized medicine.


Subject(s)
Neurology , Pharmacogenomic Testing , Attitude of Health Personnel , Child , Humans , Pharmacists , Pharmacogenetics
13.
Eur J Neurosci ; 34(2): 237-49, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21714819

ABSTRACT

Epilepsy is a heterogeneous neurological disease affecting approximately 50 million people worldwide. Genetic factors play an important role in both the onset and severity of the condition, with mutations in several ion-channel genes being implicated, including those encoding the GABA(A) receptor. Here, we evaluated the frequency of additional mutations in the GABA(A) receptor by direct sequencing of the complete open reading frame of the GABRA1 and GABRG2 genes from a cohort of French Canadian families with idiopathic generalized epilepsy (IGE). Using this approach, we have identified three novel mutations that were absent in over 400 control chromosomes. In GABRA1, two mutations were found, with the first being a 25-bp insertion that was associated with intron retention (i.e. K353delins18X) and the second corresponding to a single point mutation that replaced the aspartate 219 residue with an asparagine (i.e. D219N). Electrophysiological analysis revealed that K353delins18X and D219N altered GABA(A) receptor function by reducing the total surface expression of mature protein and/or by curtailing neurotransmitter effectiveness. Both defects would be expected to have a detrimental effect on inhibitory control of neuronal circuits. In contrast, the single point mutation identified in the GABRG2 gene, namely P83S, was indistinguishable from the wildtype subunit in terms of surface expression and functionality. This finding was all the more intriguing as the mutation exhibited a high degree of penetrance in three generations of one French Canadian family. Further experimentation will be required to understand how this mutation contributes to the occurrence of IGE in these individuals.


Subject(s)
Epilepsy, Generalized/genetics , Genetic Predisposition to Disease , Mutation , Protein Subunits/genetics , Receptors, GABA-A/genetics , Amino Acid Sequence , Animals , Base Sequence , DNA Mutational Analysis , Female , HEK293 Cells , Humans , Male , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Patch-Clamp Techniques , Pedigree , Protein Conformation , Protein Subunits/chemistry , Receptors, GABA-A/chemistry , Sequence Alignment
14.
Epilepsia ; 52(4): 728-37, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21320118

ABSTRACT

PURPOSE: The phenotypic and etiologic spectrum in adults with nodular heterotopias (NHs) has been well characterized. However, there are no large pediatric case series. We, therefore, wanted to review the clinical features of NHs in our population. METHODS: Hospital records of 31 patients with pathology or imaging-confirmed NHs were reviewed. Two-sided Fisher's exact t-test was used to assess associations between distribution of NHs and specific clinical features. KEY FINDINGS: NHs were distributed as follows: 8 (26%) unilateral focal subependymal, 3 (10%) unilateral diffuse subependymal, 5 (16%) bilateral focal subependymal, 12 (39%) bilateral diffuse subependymal, and 3 (10%) isolated subcortical. The phenotypic spectrum in our population differs from that described in adults. Significant morbidity and mortality are associated with presentation in childhood. Twenty-two of 31 patients (71%) died in the neonatal period or in childhood. Additional cerebral malformations were found in 80% and systemic malformations in 74%. The majority of patients had developmental delay, intellectual deficit, and intractable epilepsy. Patients with unilateral focal NHs were more likely to have ventriculomegaly (p = 0.027), and those with bilateral diffuse NHs more likely to have cerebellar abnormalities (p = 0.007). Isolated subcortical NHs were associated with multiple malformations (p = 0.049) and cardiac abnormalities (p = 0.027). Underlying etiology was heterogeneous and determined in only six cases (19%): del chr 1p36, del chr 15q11, pyruvate dehydrogenase deficiency, sialic acidosis type 1, Aicardi syndrome, and FLNA mutation. SIGNIFICANCE: NHs are present in childhood as part of multiple cerebral and systemic malformations; developmental delay and refractory seizures are the rule rather than the exception. Milder forms go unrecognized until seizure onset in adulthood.


Subject(s)
Cerebral Cortex/pathology , Periventricular Nodular Heterotopia/pathology , Adolescent , Adult , Child , Child, Preschool , Comorbidity , Female , Humans , Infant , Male , Periventricular Nodular Heterotopia/etiology , Periventricular Nodular Heterotopia/mortality , Young Adult
15.
Epilepsia ; 52(3): 458-66, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21204825

ABSTRACT

PURPOSE: We present two methods of implantation for the investigation of suspected insular and perisylvian epilepsy that combine depth and subdural electrodes to capitalize on the advantages of each technique. METHODS: Retrospective study of all intracranial EEG studies that included insular electrodes from 2004-2010. Patients were divided according to the implantation scheme. The first method (type 1) consisted of a craniotomy, insertion of insular electrodes after microdissection of the sylvian fissure, orthogonal implantation of mesiotemporal structures with neuronavigation, and coverage of the adjacent lobes with subdural electrodes. The second method (type 2) consisted of magnetic resonance imaging (MRI)-stereotactic frame-guided depth electrode implantation into insula and hippocampus using sagittal axes, and insertion of subdural electrodes through burr holes to cover the adjacent lobes. The combined implantations were developed and performed by one neurosurgeon (AB). KEY FINDINGS: Nineteen patients had an intracranial study that sampled the insula, among other regions. Sixteen patients were implanted using the first method, which allowed a mean of 4, 5, 20, 15, and 42 contacts per patient to be positioned into/over the insular, mesial temporal, neocortical temporal, parietal, and frontal areas, respectively. The second method (three patients) allowed a mean of 8, 7, 16, 6, and 9 contacts per patient to sample the same areas, respectively. The four patients in whom transient neurologic deficits occurred were investigated with use of type 1 implantation. SIGNIFICANCE: Combined depth and subdural electrodes can be used safely to investigate complex insular/perisylvian refractory epilepsy. Choice of implantation scheme should be individualized according to presurgical data and the need for functional localization.


Subject(s)
Electrodes, Implanted , Electroencephalography/methods , Epilepsy, Rolandic/diagnosis , Monitoring, Physiologic , Signal Processing, Computer-Assisted , Adolescent , Adult , Cerebral Cortex/physiopathology , Child , Child, Preschool , Craniotomy , Epilepsy, Rolandic/physiopathology , Epilepsy, Rolandic/surgery , Evoked Potentials/physiology , Female , Humans , Image Processing, Computer-Assisted , Imaging, Three-Dimensional , Magnetic Resonance Imaging , Male , Microdissection , Retrospective Studies , Sensitivity and Specificity , Stereotaxic Techniques , Subdural Space , Young Adult
16.
Epilepsy Behav ; 21(4): 430-6, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21705280

ABSTRACT

Consequences of status epilepticus (SE) on psychomotor development and the specific impact of the convulsive event on emerging executive functions remain controversial. Infants treated for a single episode of SE, those treated for a single febrile seizure, and healthy infants were tested with respect to motor development, language, personal, and social skills and self-regulation. The children were divided into two age groups to investigate the impact of the convulsive event at different windows of brain maturation. We found that infants who had had SE were inferior to healthy controls on the development scales. Age differentiated SE impact on visuomotor development versus sociolinguistic development. Children who had been treated for SE had significantly more difficulties delaying a response to an attractive stimulus in one of the long-delay conditions. A single episode of SE can interfere with psychomotor and cognitive development in children without previous developmental delay, and it seems that the functions that are emerging at the time of insult are most vulnerable.


Subject(s)
Brain/physiopathology , Child Development/physiology , Executive Function/physiology , Seizures, Febrile/psychology , Status Epilepticus/psychology , Age Factors , Cognition/physiology , Female , Follow-Up Studies , Humans , Infant , Male , Neuropsychological Tests , Seizures, Febrile/drug therapy , Seizures, Febrile/physiopathology , Status Epilepticus/drug therapy , Status Epilepticus/physiopathology , Treatment Outcome
17.
Seizure ; 91: 503-506, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34371246

ABSTRACT

Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. The participants were 44 infants with IS who demonstrated both absence of clinical spasms and hypsarrhythmia four weeks after starting VGB, obtained from two cohorts: 29 patients from a multicenter prospective cohort and 15 patients from a retrospective single-center cohort. We divided them post hoc into two groups according to the duration of VGB treatment: 6-month group (n=34) and >6-month group (n=10) and compared outcome between the two groups. No patient in either group had a relapse of spasms. For patients with non-identified etiology (NIE) in the 6 months treatment group, no other seizure types were observed. Late epilepsy, in the form of focal seizures, emerged in only 5/37 patients (3/30 in the 6-month treatment group; 2/7 in the extended treatment group); all within the first 6-9 months after VGB initiation. Our study provides substantial evidence that a shortened VGB course of 6 months could be sufficient to treat and prevent relapse of spasms in children with IS, particularly those with NIE.


Subject(s)
Spasms, Infantile , Vigabatrin , Anticonvulsants/adverse effects , Child , Humans , Infant , Prospective Studies , Retrospective Studies , Spasm/drug therapy , Spasms, Infantile/drug therapy , Treatment Outcome , Vigabatrin/adverse effects
18.
Seizure ; 89: 73-80, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34020345

ABSTRACT

AIM: To evaluate the long-term developmental trajectory of children with infantile spasms (IS) and identify the clinical protective and risk factors associated with their cognitive outcome. METHODS: We analyzed the five-year follow-up results of 41 children (13 female) from the previously published cohort (n = 68) recruited in a multicenter randomized controlled trial for 2-years, examining the effect of an adjunctive therapy (Flunarizine) on standardized IS treatment. The children were subsequently monitored in an open-label study for additional 3 years.  The Vineland Adaptive Behavior Scale, second edition, and either the Stanford-Binet Intelligence Scale, Fifth Edition (SB5) or the Bayley Scales of Infant Development, second edition (BSID-II) were used as cognitive outcome measures. RESULTS: Etiology was the strongest predictor of outcome. Children with no identified etiology (NIE) showed a progressive improvement of cognitive functions, mostly occurring between 2 and 5 years post-diagnosis.  Conversely, symptomatic etiology was predictive of poorer cognitive outcome. Developmental delay, other seizure types (before and after IS diagnosis), and persistent electroencephalographic abnormalities following treatment were predictive of poor cognitive outcome. INTERPRETATION: Given the 5-year cognitive improvement, children with IS should undergo a developmental assessment before school entry. Factors influencing their cognitive outcome emphasize the importance of thorough investigation and evidence-based treatment.


Subject(s)
Spasms, Infantile , Child , Clinical Protocols , Cognition , Electroencephalography , Female , Humans , Infant , Longitudinal Studies , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Spasms, Infantile/drug therapy , Treatment Outcome
19.
Ann Neurol ; 65(6): 748-53, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19557857

ABSTRACT

We sequenced genes coding for components of the SNARE complex (STX1A, VAMP2, SNAP25) and their regulatory proteins (STXBP1/Munc18-1, SYT1), which are essential for neurotransmission, in 95 patients with idiopathic mental retardation. We identified de novo mutations in STXBP1 (nonsense, p.R388X; splicing, c.169+1G>A) in two patients with severe mental retardation and nonsyndromic epilepsy. Reverse transcriptase polymerase chain reaction and sequencing showed that the splicing mutation creates a stop codon downstream of exon-3. No de novo or deleterious mutations in STXBP1 were found in 190 control subjects, or in 142 autistic patients. These results suggest that STXBP1 disruption is associated with autosomal dominant mental retardation and nonsyndromic epilepsy.


Subject(s)
Epilepsy/genetics , Intellectual Disability/genetics , Munc18 Proteins/genetics , Mutation/genetics , Adolescent , Adult , Cohort Studies , Epilepsy/complications , Epilepsy/diagnosis , Female , Humans , Intellectual Disability/complications , Intellectual Disability/diagnosis
20.
Pediatr Neurol ; 40(3): 175-80, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19218030

ABSTRACT

Seizures are an early sign of brain injury in newborns. These seizures are in most cases repetitive or associated with asymptomatic electrographic seizures. Despite the relative resistance of the immature brain to seizure-induced brain damage, there is more and more evidence that neonatal seizures impair normal brain development. This review addresses the changes associated with neonatal seizures and discusses current and future potential neuroprotective strategies.


Subject(s)
Brain Injuries/etiology , Brain/physiopathology , Seizures/complications , Seizures/pathology , Animals , Brain/abnormalities , Brain/physiology , Humans , Infant, Newborn
SELECTION OF CITATIONS
SEARCH DETAIL